Last reviewed · How we verify
NCT05052359
Aberrant Helix Pomatia Agglutinin Binding Glycan Expression in Follicular Thyroid Tumours
trial testing Lectin-histochemistry retrospectively performed in Follicular Thyroid Cancer in 37 participants. Completed in 1 September 2021.
1 August 2021
Quick facts
| Lead sponsor | National University Health System, Singapore |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 37 |
| Start date | 1 January 2018 |
| Primary completion | 1 August 2021 |
| Estimated completion | 1 September 2021 |
| Sites | 1 location across Singapore |
Drugs / interventions tested
- Lectin-histochemistry retrospectively performed
Conditions studied
- Follicular Thyroid Cancer — all drugs for Follicular Thyroid Cancer →
Sponsor
National University Health System, Singapore
Who can join
18 and older, any sex, with Follicular Thyroid Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Aberration of glycosylation is a hallmark of cancer cells, and plays an important role in oncogenesis and cancer progression, including metastasis. One of the markers of aberrant glycosylation (O-linked) is the binding of the lectin Helix pomatia agglutinin (HPA), which has been demonstrated in a wide range of human cancers, especially in tumours with a more aggressive phenotype. Data on the role of HPA within follicular neoplasms of the thyroid gland are currently lacking, therefore we sought to investigate possible changes in cell surface glycosylation associated with this type of neoplasms.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT05052359
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Follicular Thyroid Cancer
Currently open trials in the same condition.
- NCT05668962 — Restor. I-131 Upt. + Selpercatinib in RET F-P RAI-R TC · Phase 2 · recruiting
- NCT05463107 — Correlation Between Various Urinary Exosomal Protein Biomarkers and Pathological Manifestation in Thyroid Follicular Neo · active not recruiting
- NCT04948437 — Urinary Exosomal Biomarkers of Thyroglobulin and Galectin-3 for Prognosis and Follow-up in Patients of Thyroid Cancer · active not recruiting
- NCT04544111 — PDR001 Combination Therapy for Radioiodine-Refractory Thyroid Cancer · Phase 2 · active not recruiting
- NCT00001160 — Studies on Tumors of the Thyroid · recruiting
Other National University Health System, Singapore trials
Trials by the same sponsor.
- NCT07168343 — Effectiveness of Two Icodextrin Exchanges on Fluid Status and Blood Pressure Control Compared to a Single Icodextrin Exc · NA · not yet recruiting
- NCT06999876 — The Effect of Combined Transcranial Pulse Current Stimulation (tPCS) and Transcutaneous Electrical Nerve Stimulation (TE · NA · not yet recruiting
- NCT07134595 — Comparing Conventional Continuous Ambulatory Peritoneal Dialysis Prescription (C-CAPD) With Modified-CAPD (M-CAPD) Presc · NA · recruiting
- NCT05969639 — Improving Dietary Habit and Weight Loss in Young Adults With Overweight and Obesity: The Healthy Eating for Young Adults · NA · unknown
- NCT06542718 — Studying Phenotypes of Gestational Diabetes Mellitus in an Asian Pregnant Cohort · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05052359 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by National University Health System, Singapore
- Last refreshed: 1 October 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05052359.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing